In our previous studies, it was demonstrated that the activity of a ribozyme in vivo was governed by several parameters, which include a high level-expression of ribozyme, the intracellular stability of the ribozyme and colocalization of the ribozyme with its target RNA in the same cellular compartment. To generate ribozymes with significant activity in vivo, we have developed a ribozyme-expression system based on a human tRNA Val promoter. Our tRNA-embedded ribozymes produced by our ribozyme-expression system remain relatively stable in cultured cells with half-lives longer than 30 min. Moreover, tRNA-ribozymes with a cloverleaf structure were efficiently exported from the nucleus to the cytoplasm, where they would effectively cleave target RNAs. In the present study, we investigated the relationship between the secondary structure of the tRNA-ribozymes and the transport efficacy of them in mammalian cells by using a screening system in vivo. Furthermore, we also investigated the mechanism of the export of tRNA-embedded ribozymes both in mammalian cells and in Xenopus oocytes.
INTRODUCTION
A number of macromolecules continuously move between the nucleus and the cytoplasm through the nuclear pore complexes (NPCs) in eukaryotic cells. In general, cellular RNA species are transcribed as precursors and subsequently processed to mature molecules in the nucleus. The mature RNAs are exported by means of saturable carriers into the cytoplasm to participate in the protein synthesis. To date, many investigations have provided evidences that the nuclear tRNA export requires a tRNA export receptor, named exportin-tRNA (Xpo-t) (1, 2) , in combination with a small GTPase Ran (RanGTP) which is essential for almost all the nuclearcytoplasmic transports. Newly synthesized tRNAs undergo a series of maturation steps in the nucleus that involve processing of the 5' and 3' ends, base modifications, the attachment of the CCA at the 3' end and, in some cases, the removal of a small intron. Xpo-t can recognize specifically the 3' acceptor stem and T\|/C loop of a mature tRNA (3). Furthermore, it was suggested that, in Xenopus oocytes, the aminoacylation step of tRNAs in the nucleus prevents the pre-tRNAs from export to the cytoplasm and, in addition, promotes the transport of the mature tRNA to the cytoplasm, acting as a proofreading mechanism (4) .
A hammerhead ribozyme is one of the smallest catalytic RNA molecules that can cleave target RNAs at specific sites. A number of mechanistic studies and studies directed these attractive tools towards the application in vivo have been performed. To maintain both high level of expression and intracellular stability of the ribozyme, we established a tRNA-based ribozyme-expression system (5-9). In this system, a ribozyme sequence was attached at downstream of the wild-type tRNA Val whose last seven bases were substituted with an artificial linker to avoid trimming of the tRNA-like transcripts. The secondary structure of a tRNA Val -ribozyme, which determines the activity of the ribozyme in vivo, was controlled by the linker sequence via the formation of stable stems in combination with the tRNA Val sequence. In mammalian cells, the ribozymes containing cloverleaf structures were extremely effective because of their efficient export from the nucleus to the cytoplasm (5-9), where they could be ensured colocalization with their target RNAs. In contrast, ribozymes without cloverleaf structures were not exported into the cytoplasm, thereby they were less effective. Therefore, to investigate more detail about the structurefunction relationship of tRNA-ribozyme transcripts and to construct more effective ribozyme-expression systems, we have investigated the transport mechanism of tRNAribozyme transcripts. In addition, we are attempting to evaluate the sequence specificities and the structural properties of the linker region that contributed to the ribozyme activity in vivo, by using a unique screening system in vivo.
RESULTS AND DISSCUSION Accumulating data in our laboratory indicated that tRNA
Valribozymes with a cloverleaf structure were efficiently exported from the nucleus to the cytoplasm in cultured cells. Then, to demonstrate that the transported tRNA-ribozymes had indeed maintained the expected structure, we constructed a screening system for the transported tRNAribozyme transcripts (Fig.l) . We designed expressionvectors encoding tRNA-ribozymes with 22 random sequences at the linker sequence for screening of the efficiently transported tRNA-ribozyme transcripts. We substituted the sequence of linker region with the random sequence since the secondary structure of tRNA-ribozymes was dramatically affected by this linker sequence. Both nuclear and cytoplasmic RNAs were separated from HeLa cells that had been transfected with the screening vectors. After the subsequent cloning of each tRNA-ribozyme transcript, sequences of the tRNA-ribozyme region were determined. We further predicted the secondary structure of each tRNA-ribozyme, separated from either nuclear or cytoplasmic fractions, based on the computer-folding program. As expected, it was demonstrated that the cloverleaf structure was maintained in the tRNA-ribozymes selected from the cytoplasmic fraction but not in the tRNAribozymes selected from the nuclear fraction.
We are interested in the difference in the mechanism of the tRNA-ribozyme transport between mammalian cells and Xenopus oocytes since our tRNA ribozymes were apparently exported to the cytoplasm in mammalian cells but not in Xenopus oocytes. We therefore examined the transport of the ribozyme. We found some similarity and dissimilarity in the mechanism of the tRNA-ribozyme transport in HeLa cells and Xenopus oocytes.
The tRNA-embedded ribozymes, which have a cloverleaf structure and are regarded as immature tRNAs, can be efficiently exported into the cytoplasm in mammalian cells, although it was reported that immature tRNAs were not export to the cytoplasm in Xenopus oocytes. However, based on our accumulating data, we want to emphasize that a tRNA Val -ribozyme can be exported to the cytoplasm through the tRNA export pathway using Xpo-t in mammalian cells.
